Antitrust News & Notes is a bi-monthly report concerning recent developments, issues, and matters of interest in antitrust law and competition policy. To access your copy of the most current issue, follow this link.

In this issue, we examine some emerging trends involving federal antitrust enforcement:

• Despite Recent Developments in Generic Pharmaceutical Reverse-Payment Cases, Future Remains Murky
  We review how, despite the U.S. Supreme Court’s recent refusal to revive a challenge to a reverse-payment settlement, the FTC and others appear primed to continue challenging the use of such settlements to resolve pharmaceutical patent disputes.
  
  
• Justice Department’s First Monopolization Case in a Decade Challenges Dominant Hospital’s Contracting Practices
  We examine the Justice Department’s return to Section 2 enforcement litigation, and what it says for health care providers.
  
  
• FTC Report Recommends Changes to U.S. Patent System to Promote Competition and Innovation
  We discuss a new FTC report advocating changes to the nation’s intellectual property regime meant to ameliorate the tension between robust patent enforcement and lively competitive innovation.
  

For more information on these, or any other antitrust topics, please contact editor Jason Powers, or V&E partners Jim Reeder or William Vigdor, or e-mail one of our Antitrust practice contacts. Visit our website to learn more about V&E's Antitrust practice. Access prior issues of Antitrust News & Notes here.